Latest news with #RameshSwaminathan
Time of India
01-05-2025
- Business
- Time of India
Lupin selects Hewlett Packard Enterprise to accelerate innovation and optimize cloud costs
Hewlett Packard Enterprise today announced that global pharma major Lupin Limited (Lupin) headquartered in Mumbai, India, has selected HPE Private Cloud Enterprise for a fully managed turnkey solution that modernizes its private cloud infrastructure to accelerate innovation and enables them to seamlessly repatriate workloads from the public cloud. This reinforces HPE's leadership in private cloud adoption and its commitment to empowering enterprises with cloud-native solutions . Lupin, an existing HPE GreenLake cloud customer, has selected the HPE Private Cloud Enterprise solution to reduce its overall IT expenditure without compromising on the cloud experience. The integration of HPE's solution will enable data sovereignty, operational efficiency , faster innovation, and energy efficiency. HPE Managed Services will not only oversee SAP S/4 HANA instances running on HPE systems but also manage the network and security setup in data centers for Lupin. ' HPE Private Cloud Enterprise is perfectly aligned with our business objectives, offering the flexibility, security, and efficiency needed to facilitate our growth and consistently provide high-quality products to our customers,' said Ramesh Swaminathan, Executive Director, Global CFO & Head of API Plus SBU, Lupin. 'It signifies a strategic move that promises efficiency and cost savings.' "Our partnership with Lupin reinforces our innovation and commitment to remaining the leader in hybrid and private cloud solutions. It demonstrates the value of our efforts and the trust our clients place in us,' said Som Satsangi, SVP and managing director, HPE India. "This collaboration underscores HPE's commitment to enabling enterprises with cutting-edge cloud solutions that drive business success. As more organizations in India embrace private cloud for its security, control, and efficiency, HPE remains at the forefront of this digital shift." The implementation of HPE Private Cloud Enterprise will provide Lupin with several key benefits: Enhanced Operational Efficiency: By hosting core applications in data centers and edge applications at manufacturing plants, the platform will streamline operations, reduce downtime, and increase production efficiency. The private cloud's templatised approach enables rapid rollouts and automates provisioning, significantly reducing repetitive tasks. Improved Data Sovereignty and Security: Migrating public cloud workloads to an on-premises cloud will provide robust data protection and compliance with regulatory requirements, a critical factor for customer trust in the pharmaceutical industry. The solution's application-aware, highly available infrastructure is designed with built-in security, providing Lupin a resilient and secure environment for critical workloads. Faster Innovation Cycles: The scalable and flexible nature of the private cloud will empower Lupin to innovate and launch new solutions faster, ensuring customers have quicker access to life-saving treatments. This agility will also empower the IT team to swiftly align its strategy with evolving business priorities and product mix. Localized Insights for Quality Control: Edge applications will enhance real-time monitoring and analytics at manufacturing plants, improving quality assurance and ensuring consistent product excellence for end customers. By leveraging edge computing with centralized management, data can be processed locally at the edge while the control plane remains centralized, ensuring efficient oversight and streamlined operations. Sustainability and Cost Optimization: By centralizing and optimizing workloads, the solution will reduce operational costs and carbon footprints, enabling Lupin to achieve more sustainable operations and pass on the benefits of efficiency and affordability to its customers. With a cost structure aligned to usage, the solution also addresses the business demand for application-level cost visibility, ensuring better financial oversight and accountability. These benefits will collectively enhance the efficiency, security, and innovation of Lupin's operational framework.
Hindustan Times
28-04-2025
- Health
- Hindustan Times
Medicine used in drug-resistant TB treatment 25% cheaper
The price of pretomanid, a key component used in the treatment of drug-resistant tuberculosis (TB), dropped by 25% in April, to less than $1 per day, primarily owing to Indian manufacturers joining in, people familiar with the matter said. Experts see this as an important development given the pressures on health spending in high-burden countries. Pretomanid is a key component of the BPaL/M, a shorter and more effective regimen that the Union government has also recently introduced in the national TB programme. TB Alliance, a non-profit that developed pretomanid, in a statement said the price drop of the key drug reflects ongoing efforts by the organisation and its partners 'to broaden access and improve affordability through a multi-manufacturer approach to access.' TB Alliance further said it has pioneered an innovative access model by partnering with multiple quality-assured manufacturers. 'This strategy helped launch pretomanid at an initial low price and ensured rapid, sustainable, and affordable access across high-TB burden countries. Simultaneously, by enabling healthy competition and fostering multiple high-quality supply sources, TB Alliance's strategy expanded availability while driving down costs,' the statement added. BPaL/M is a six-month all-oral regimen recommended by the World Health Organization (WHO) to treat most forms of drug-resistant TB. It consists of bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M). Pretomanid is now available through the Global Drug Facility (GDF) at just $169 per treatment course (of six month), effectively making it less than $1 per day, a key pricing benchmark identified by the global TB advocacy community. The drug was initially sold for $364 per treatment course after its approval in 2019, which was reduced to $224 in October 2024. The current GDF price reduction, led by Lupin Limited, represents a crucial step in delivering on this vision, said the statement. Procurement through GDF will save an estimated $37 million annually according to The Stop TB Partnership, the organisation responsible for managing GDF, allowing for the treatment of an additional 120,000 people with DR-TB. Together with recent price reductions for the other regimen components, the cost of a full BPaL/M treatment course has dropped to a new low of $310—less than $2 per day, and a 47% reduction from its December 2022 price. 'Lupin is proud to collaborate with TB Alliance and the Global Drug Facility to make pretomanid, an essential medicine in the fight against multidrug-resistant TB, more accessible and affordable for TB patients across the globe,' said Ramesh Swaminathan, global CFO, executive director, head of API Plus SBU, Lupin, in a statement. 'The recent price reduction reflects our strong and deep-rooted commitment to delivering high-quality and affordable medicines to TB patients worldwide. Through this partnership, we reaffirm our dedication to patient-centric innovation and equitable access, ensuring that countries burdened by TB have the necessary treatment options they need to save lives and strengthen public health systems.'
Yahoo
23-04-2025
- Business
- Yahoo
Lupin Selects Hewlett Packard Enterprise to Accelerate Innovation and Optimize Cloud Costs
HPE Private Cloud Enterprise will enhance scalability and operational performance for Lupin. BENGALURU, India, April 23, 2025--(BUSINESS WIRE)--Hewlett Packard Enterprise (NYSE: HPE) today announced that global pharma major Lupin Limited (Lupin) headquartered in Mumbai, India, has selected HPE Private Cloud Enterprise for a fully managed turnkey solution that modernizes its private cloud infrastructure to accelerate innovation and enables them to seamlessly repatriate workloads from the public cloud. This reinforces HPE's leadership in private cloud adoption and its commitment to empowering enterprises with cloud-native solutions. Lupin, an existing HPE GreenLake cloud customer, has selected the HPE Private Cloud Enterprise solution to reduce its overall IT expenditure without compromising on the cloud experience. The integration of HPE's solution will enable data sovereignty, operational efficiency, faster innovation, and energy efficiency. HPE Managed Services will not only oversee SAP S/4 HANA instances running on HPE systems but also manage the network and security setup in data centers for Lupin. "HPE Private Cloud Enterprise is perfectly aligned with our business objectives, offering the flexibility, security, and efficiency needed to facilitate our growth and consistently provide high-quality products to our customers," said Ramesh Swaminathan, Executive Director, Global CFO & Head of API Plus SBU, Lupin. "It signifies a strategic move that promises efficiency and cost savings." "Our partnership with Lupin reinforces our innovation and commitment to remaining the leader in hybrid and private cloud solutions. It demonstrates the value of our efforts and the trust our clients place in us," said Som Satsangi, SVP and managing director, HPE India. "This collaboration underscores HPE's commitment to enabling enterprises with cutting-edge cloud solutions that drive business success. As more organizations in India embrace private cloud for its security, control, and efficiency, HPE remains at the forefront of this digital shift." The implementation of HPE Private Cloud Enterprise will provide Lupin with several key benefits: Enhanced Operational Efficiency: By hosting core applications in data centers and edge applications at manufacturing plants, the platform will streamline operations, reduce downtime, and increase production efficiency. The private cloud's templatised approach enables rapid rollouts and automates provisioning, significantly reducing repetitive tasks. Improved Data Sovereignty and Security: Migrating public cloud workloads to an on-premises cloud will provide robust data protection and compliance with regulatory requirements, a critical factor for customer trust in the pharmaceutical industry. The solution's application-aware, highly available infrastructure is designed with built-in security, providing Lupin a resilient and secure environment for critical workloads. Faster Innovation Cycles: The scalable and flexible nature of the private cloud will empower Lupin to innovate and launch new solutions faster, ensuring customers have quicker access to life-saving treatments. This agility will also empower the IT team to swiftly align its strategy with evolving business priorities and product mix. Localized Insights for Quality Control: Edge applications will enhance real-time monitoring and analytics at manufacturing plants, improving quality assurance and ensuring consistent product excellence for end customers. By leveraging edge computing with centralized management, data can be processed locally at the edge while the control plane remains centralized, ensuring efficient oversight and streamlined operations. Sustainability and Cost Optimization: By centralizing and optimizing workloads, the solution will reduce operational costs and carbon footprints, enabling Lupin to achieve more sustainable operations and pass on the benefits of efficiency and affordability to its customers. With a cost structure aligned to usage, the solution also addresses the business demand for application-level cost visibility, ensuring better financial oversight and accountability. These benefits will collectively enhance the efficiency, security, and innovation of Lupin's operational framework. About Hewlett Packard Enterprise Hewlett Packard Enterprise (NYSE: HPE) is a global technology leader focused on developing intelligent solutions that allow customers to capture, analyze, and act upon data seamlessly. The company innovates across networking, hybrid cloud, and AI to help customers develop new business models, engage in new ways, and increase operational performance. For more information, visit: About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn View source version on Contacts Editorial Contact:Harleen Sachdeva Sign in to access your portfolio
Business Wire
23-04-2025
- Business
- Business Wire
Lupin Selects Hewlett Packard Enterprise to Accelerate Innovation and Optimize Cloud Costs
BENGALURU, India--(BUSINESS WIRE)-- Hewlett Packard Enterprise (NYSE: HPE) today announced that global pharma major Lupin Limited (Lupin) headquartered in Mumbai, India, has selected HPE Private Cloud Enterprise for a fully managed turnkey solution that modernizes its private cloud infrastructure to accelerate innovation and enables them to seamlessly repatriate workloads from the public cloud. This reinforces HPE's leadership in private cloud adoption and its commitment to empowering enterprises with cloud-native solutions. Lupin, an existing HPE GreenLake cloud customer, has selected the HPE Private Cloud Enterprise solution to reduce its overall IT expenditure without compromising on the cloud experience. The integration of HPE's solution will enable data sovereignty, operational efficiency, faster innovation, and energy efficiency. HPE Managed Services will not only oversee SAP S/4 HANA instances running on HPE systems but also manage the network and security setup in data centers for Lupin. ' HPE Private Cloud Enterprise is perfectly aligned with our business objectives, offering the flexibility, security, and efficiency needed to facilitate our growth and consistently provide high-quality products to our customers,' said Ramesh Swaminathan, Executive Director, Global CFO & Head of API Plus SBU, Lupin. 'It signifies a strategic move that promises efficiency and cost savings.' "Our partnership with Lupin reinforces our innovation and commitment to remaining the leader in hybrid and private cloud solutions. It demonstrates the value of our efforts and the trust our clients place in us,' said Som Satsangi, SVP and managing director, HPE India. "This collaboration underscores HPE's commitment to enabling enterprises with cutting-edge cloud solutions that drive business success. As more organizations in India embrace private cloud for its security, control, and efficiency, HPE remains at the forefront of this digital shift." The implementation of HPE Private Cloud Enterprise will provide Lupin with several key benefits: Enhanced Operational Efficiency: By hosting core applications in data centers and edge applications at manufacturing plants, the platform will streamline operations, reduce downtime, and increase production efficiency. The private cloud's templatised approach enables rapid rollouts and automates provisioning, significantly reducing repetitive tasks. Improved Data Sovereignty and Security: Migrating public cloud workloads to an on-premises cloud will provide robust data protection and compliance with regulatory requirements, a critical factor for customer trust in the pharmaceutical industry. The solution's application-aware, highly available infrastructure is designed with built-in security, providing Lupin a resilient and secure environment for critical workloads. Faster Innovation Cycles: The scalable and flexible nature of the private cloud will empower Lupin to innovate and launch new solutions faster, ensuring customers have quicker access to life-saving treatments. This agility will also empower the IT team to swiftly align its strategy with evolving business priorities and product mix. Localized Insights for Quality Control: Edge applications will enhance real-time monitoring and analytics at manufacturing plants, improving quality assurance and ensuring consistent product excellence for end customers. By leveraging edge computing with centralized management, data can be processed locally at the edge while the control plane remains centralized, ensuring efficient oversight and streamlined operations. Sustainability and Cost Optimization: By centralizing and optimizing workloads, the solution will reduce operational costs and carbon footprints, enabling Lupin to achieve more sustainable operations and pass on the benefits of efficiency and affordability to its customers. With a cost structure aligned to usage, the solution also addresses the business demand for application-level cost visibility, ensuring better financial oversight and accountability. These benefits will collectively enhance the efficiency, security, and innovation of Lupin's operational framework. About Hewlett Packard Enterprise Hewlett Packard Enterprise (NYSE: HPE) is a global technology leader focused on developing intelligent solutions that allow customers to capture, analyze, and act upon data seamlessly. The company innovates across networking, hybrid cloud, and AI to help customers develop new business models, engage in new ways, and increase operational performance. For more information, visit: About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
